Leishmaniasis is a protozoan parasitic disease that affects 12 million people worldwide. The first line choice for the treatment of this disease is antimonial drugs. In the endemic regions, resistance to this class of drugs is a major impediment to treatment. Microbes often become resistant to drugs by mutation or down-regulation of uptake systems, but the uptake system for the antimonial drugs in Leishmania is unknown. In other organisms, aquaglyceroporins have been shown to facilitate uptake of trivalent metalloids. In this study, we report the identification and characterization of aquaglyceroporins from Leishmania major (LmAQP1) and Leishmania tarentolae (LtAQP1), respectively. These Leishmania proteins have the conserved signature motifs of aquaglyceroporins. Transfection of LmAQP1 into three species of Leishmania, L. tarentolae, Leishmania infantum, and L. major, produced hypersensitivity to both As(III) and Sb(III) in all three strains. Increased production of LmAQP1 was detected by immunoblotting. Drug-resistant parasites with various mutations leading to resistance mechanisms became hypersensitive to both metalloids after expression of LmAQP1. Increased rates of uptake of As(III) or Sb(III) correlated with metalloid sensitivity of the wild type and drug-resistant transfectants. Transfection of LmAQP1 in a Pentostam-resistant field isolate also sensitized the parasite in the macrophage-associated amastigote form. One allele of LmAQP1 was disrupted in L. major, and the resulting cells became 10-fold more resistant to Sb(III). This is the first report of the uptake of a metalloid drug by an aquaglyceroporin in Leishmania, suggesting a strategy to reverse resistance in the field.
Leishmaniasis is a parasitic disease caused by the protozoan parasite Leishmania sp. Leishmaniasis is a spectrum of diseases in which each disease is distinctly manifested, and all have potentially devastating consequences: disfigurement, damage to internal organs, and death (1) . In the last two decades, visceral leishmaniasis especially has been widely recognized as an opportunistic infection in immunocompromised patients, particularly those who are infected with human immunodeficiency virus (1, 2) . The first line choice of treatment against all forms of leishmaniasis uses drugs containing pentavalent antimony such as sodium stibogluconate (Pentostam) and meglumine antimonate (Glucantime). Clinical resistance to this class of drugs, however, has been reported from many parts of the world (3). More than 50% of the cases of visceral leishmaniasis in Northeast India are resistant to pentavalent antimonials (4) . Resistance to pentavalent antimonials in Leishmania is a priority of the World Health Organization (www.who.int/infectious-disease-report/2000). Leishmania resistant to trivalent antimony has also been reported in vitro, which has provided an excellent model for the study of resistance mechanisms (5) . Although the mechanism of action of Sb(V) is still unclear, it is generally believed that Sb(V) must be reduced to Sb(III) to be effective in vivo (6) . Whether Sb(V) is reduced to Sb(III) in Leishmania amastigotes or in host macrophages is controversial. In 2001, Shaked-Mishan et. al. (7) reported isolating a Pentostam-resistant Leishmania donovani strain that lacks the antimoniate (Sb(V)) reduction, although no enzyme was associated with this activity. Reduction could occur enzymatically as a thiol-dependent reductase found in Leishmania (8) , by other types of reductases as in yeast (9) , or reduction could occur non-enzymatically by intracellular thiols in the parasite or host (10) . If reduction occurs in the macrophage then the reduced form Sb(III) would have to be transported into the parasite to be effective. To date, however, no Sb(III) uptake system has been identified in Leishmania.
Resistance is an interplay between uptake, efflux, and sequestration. Down-regulation of an uptake system can result in acquired resistance. Aquaglyceroporins (AQPs) 1 have recently been identified as uptake systems for trivalent metalloids in eukaryotes and prokaryotes (11) (12) (13) . AQPs, which are channels for small neutral solutes, are members of the aquaporin superfamily (14) . Mammalian AQP9 has the broadest specificity and transports water, glycerol, urea, carbamides, polyols, purines, and pyrimidines in a manner that is sensitive to phloretin and mercury (14, 15 Escherichia coli, was first identified as an uptake pathway for Sb(III) (11) . Disruption of the Saccharomyces cerevisiae FPS1 gene, which encodes an AQP homologue, similarly leads to resistance to trivalent metalloids (12) . Recently, we have shown that mammalian AQP7 and AQP9 facilitate uptake of As(III) and Sb(III) when expressed in either S. cerevisiae or oocytes (13) . Given that the pK a values for the hydroxides of As(III) and Sb(III) are 9.2 and 11.8, respectively, the anions arsenite and antimonite do not exist in solution at a neutral pH level. We have shown that the species present in solution is As(OH) 3 (16) , but minor polymeric species probably also exist (17) .
The purpose of this study was two-fold. First, no aquaglyceroporin homologue has been identified in any Leishmania species. Second, the route of uptake of the activated form of the anti-Leishmania drug Pentostam is unknown. In this study we report for the first time the identification of a leishmanial homologue of the mammalian AQP9 and demonstrate that it is responsible for the uptake of trivalent antimony. LtAQP1 (GenBank TM accession number AY338876) and LmAQP1 (GenBank TM accession number AY567835) were identified from Leishmania tarentolae and Leishmania major, respectively. These exhibit 76% identity and 90% overall similarity to each other. LmAQP1 was expressed in promastigotes from three different species of Leishmania. Each of the transfectants produced substantial amounts of LmAQP1 and became hypersensitive in vitro to As(III) and Sb(III). LmAQP1 expression in a variety of As(III)-or Sb(III)-resistant mutants restored metalloid sensitivity in every strain, independently of the mechanism of resistance. The results of transport studies suggest that this hypersensitivity is caused by an increased rate of uptake of Sb(III) or As(III) in the promastigotes, consistent with increased amounts of the LmAQP1 channel. Disruption of one of the two AQP1 alleles in L. major conferred a 10-fold increase in resistance to trivalent antimony compared with the wild type. These results suggest that a major route of entry of trivalent antimony, the activated form of Pentostam, into Leishmania is catalyzed by AQP1. Importantly, the results demonstrate that a loss of AQP1 can produce resistance and that increased expression of AQP1 in drug-resistant parasites can reverse resistance.
EXPERIMENTAL PROCEDURES
Reagents and Media-All reagents were from Sigma. As(III) and Sb(III) were purchased in the form of sodium arsenite and potassium antimonyl tartrate. DNA manipulation reagents were obtained from Qiagen and Invitrogen. Semi-defined medium 79 for growth of Leishmania promastigotes was prepared as described previously (18) .
Cell Lines and Cultures-All species of Leishmania were maintained in Semi-defined medium 79 at 25°C as promastigotes. For the pathogenic species L. major (LV39) and L. infantum, the medium was supplemented with 10 M 6-biopterin. The L. tarentolae drug-resistant mutants LtarAs50.1 (selected for resistance to As(III)) and LtarSb400.1 (selected for resistance to Sb(III)) have been described previously (19, 20) . The cell line LinfAs200.1 was selected in the presence of sodium arsenite by in vitro stepwise selection. This cell line grows in the presence of 150 M arsenite and is cross-resistant to potassium antimonyl tartrate (Table I ). All the transfectants were maintained in the presence of 120 g/ml geneticin (G418, Invitrogen).
Cloning of Full-length LmAQP1 and LtAQP1-The Leishmania Genome Network gene data base (www.genedb.org/genedb) was inspected for an L. major homologue of human AQP9. Five putative aquaporin homologues were found. The closest homologue to AQP9 (systematic name LmjF31.0020) is 945 bp in length. When the putative reading frame was aligned with human or rat AQP9, there were several possible sites of translational initiation that could add as much as 99 bp to the 5Ј end of the gene. To identify the N and C termini of the protein, 5Ј and 3Ј rapid amplification of cDNA ends (RACE) was performed.
The 3Ј end was mapped by the 3Ј-RACE method using a kit from Ambion. The cDNA was synthesized from 1 g of total RNA isolated from L. tarentolae using a primer for the 3Ј adapter provided by the manufacturer according to their protocol. The 3Ј-RACE reaction was performed using Taq DNA polymerase (Invitrogen) and a forward genespecific primer (FO2, 5Ј-GGACTACTGTTGTTTGTGATTGG-3Ј) and a reverse 3Ј-RACE outer primer provided by Ambion. PCR reactions were performed in a Peltier Thermal Cycler (PTC 200) from MJ Research.
The 5Ј end of LtAQP1 cDNA was determined by the RNA ligasemediated (RLM) RACE method, using a First Choice TM RLM-RACE kit from Ambion following the manufacturer's protocol. L. tarentolae total RNA was first treated with calf intestinal phosphatase to remove 5Ј-phosphates from ribosomal RNA, fragmented mRNA, tRNA, and contaminating genomic DNA for 5Ј-RLM-RACE. The cap structure found on intact 5Ј ends of mRNA was not affected by calf intestinal phosphatase. The RNA was then treated with tobacco acid pyrophosphatase to remove the cap structure, leaving a 5Ј-monophosphate. A 45-bp RNA adapter oligonucleotide was ligated to the RNA population using T4 RNA ligase. The adapter could not ligate to dephosphorylated RNA because these molecules lack the 5Ј-phosphate necessary for ligation. A random primed reverse transcription was performed using Molony murine leukemia virus reverse transcriptase from Ambion followed by nested PCR to amplify the 5Ј end of the transcript. The PCR reaction was performed using an antisense gene-specific primer (FO 5Ј-3, 5Ј-GTGACAAATCGCGTGCCCCCAACTC-3Ј). All PCR products were gelpurified, cloned into pGEM-T Easy vector (Promega), and sequenced (CEQ 2000 from Beckman Coulter). Full-length (846 bp) LtAQP1 could be generated from overlapping RLM-RACE and 3Ј-RACE PCR fragments. The reading frame from LtAQP1 was aligned with that of LmjF31.0020 to identify the N and C termini. The DNA sequence from the Leishmania gene data base was used to design forward (5Ј-TCTA-GAATGCATGAGGAAGAGGAGGACC-3Ј) and reverse (5Ј-AAGCT-TCTAACAGCTGGGCGGAATG-3Ј) primers (with XbaI at the 5Ј and HindIII at the 3Ј ends), which were used to clone the 846-bp fragment from total DNA of L. major by PCR. The fragment was cloned into pGEM-T Easy vector (LmAQP1/pGEMEasy) and sequenced.
Cloning of LmAQP1 in Leishmania Expression Vector pSP72␣neo␣-pSP72␣neo␣ was created on the backbone of pSP72 (Promega) and pGEM7␣neo␣ vectors. pGEM7␣neo␣ was created as described previously (21) . In this study, the BamHI-SmaI fragment of pGEM7␣neo␣ was cloned into the same sites of pSP72 to create pSP72␣neo␣. LmAQP1/pGEMEasy was digested with XbaI and HindIII and cloned into the same sites of pSP72␣neo␣, giving rise to pSP-AQPneo.
Disruption of an LmAQP1 Allele in L. major-An 1830-bp fragment with ϳ500-bp upstream and downstream sequences of LmAQP1 was cloned from L. major total DNA by PCR. The fragment was sequenced to confirm the integrity. A 786-bp sequence of LmAQP1 was replaced with a neomycin cassette. The fragment containing the neomycin cassette was linearized and transfected into wild type L. major. Clones resistant to geneticin (G418) were selected. Total DNA was digested with SphI and analyzed by Southern blotting (22) , with a DNA probe consisting of the 5Ј flanking region of LmAQP1 and a second one specific to the neomycin cassette (see Fig. 6A ).
Western Blot Analysis-An anti-LmAQP1 rabbit antibody against a peptide corresponding to residues 139 -152 of LmAQP1 was synthesized by Covance Corp. (Denver, PA). Plasma membranes were prepared from Leishmania infantum and L. tarentolae transfected with vector alone or LmAQP1 as described previously (23) . Total membrane protein was estimated using Amido Black (24) . Membranes (350 g) were analyzed by SDS-PAGE on 10% acrylamide gels (25) . The proteins were transferred to a nitrocellulose membrane and probed with the anti-peptide antibody at 1:4000 dilution, performed as described previously (9) . Transfection of LmAQP1 in Leishmania-Transfection of pSPAQPneo into the Leishmania promastigotes was accomplished as described previously (26) . Selections were performed with 120 g/ml geneticin (G418) from Invitrogen.
Metalloid Sensitivity Assays-Metalloid sensitivity of the promastigote transfectants and the single LmAQP1 knock-out strain was determined as described previously (27) . Log phase promastigote cultures were diluted to 10 6 cells/ml in Semi-defined medium 79 containing various concentrations of As(III) in the form of sodium arsenite or Sb(III) in the form of potassium antimonyl tartrate. Growth was monitored from the absorbance at 600 nm after 5 days. EC 50 was calculated from the slope of the linear regression of absorbance versus metalloid concentration. Each assay was performed three times. Error bars were calculated from the mean Ϯ S.E.
Metalloid sensitivity of amastigotes inside macrophages was achieved by co-transfecting a field-resistant L. donovani strain, isolated from a patient from Bihar who did not respond to pentavalent antimony chemotherapy, with LmAQP1 and firefly luciferase gene as described previously (28) . THP-1 cells were cultured in RPMI 1640 medium until the cells were confluent followed by treatment with phorbol 12-myristate 13-acetate. Phorbol 12-myristate 13-acetate was washed with prewarmed medium and then infected with luciferase expressing stationary-phase promastigotes overexpressing AQP1 or vector alone, at a parasite to macrophage ratio of 10:1. After incubation at 37°C with 5% CO 2 for 2 h, non-internalized parasites were washed away, and infected macrophages were treated with different concentrations of Pentostam. Macrophages were lysed and 20 l of the lysate were mixed with luciferase assay buffer and transferred to a luminometer plate, and luciferase activity was measured in a microtiter plate luminometer. Values are expressed as relative light units. EC 50 was determined by plotting the percentage of relative light units as a function of drug concentration. Error bars were calculated from the mean Ϯ S.E.
Uptake Assays-Log phase Leishmania promastigotes were washed twice with phosphate-buffered saline, pH 7.4, (Invitrogen) and suspended in phosphate-buffered saline containing 10 mM glucose at a density of 5 ϫ 10 7 cells/ml. Promastigotes were then incubated with 100 M As(III) or Sb(III) for 10 min at 27°C. An 0.5-ml portion was washed twice with the same volume of ice-cold phosphate-buffered saline, pelleted by centrifugation at 17,000 ϫ g for 1 min at room temperature, dried, digested with 0.05 ml of 70% nitric acid for 2 h at 70°C, diluted to 5 ml with high pressure liquid chromatography water, and then analyzed by inductively coupled plasma mass spectroscopy (Elan 9000, PerkinElmer Life Sciences) as described previously (29) . Each transport experiment was repeated three times with duplicate samples. Error bars were calculated from the mean Ϯ S.E.
RESULTS

Identification and Cloning of LmAQP1-The Leishmania
Genome Network gene data base contains five L. major sequences for aquaporin homologues. Four of the sequences are more similar to aquaporin water channels than to aquaglyceroporins. Only the fifth (systematic name LmjF31.0020), located in chromosome 31, has significant sequence similarity to aquaglyceroporins. This 314-residue protein sequence from L. major, which we designated LmAQP1, has a potential 33-residue (MNSPTTMPLQCH-DAETQLYVDKESPEGLPIGNQ) N-terminal extension when aligned with human or rat AQP9. To identify the likely N and C termini of the L. major and the L. tarentolae homologue, 5Ј-RLM-RACE and 3Ј-RACE PCR were performed with total RNA isolated from L. tarentolae. Clear bands were observed from 5Ј-RLM-RACE and 3Ј-RACE PCR, respectively, using overlapping primers. These fragments were cloned and sequenced, giving rise to an 846-bp gene that we designated LtAQP1. Alignment of LtAQP1 with LmAQP1 suggested that the N terminus of the latter starts from the third methionine. LmAQP1 was subsequently cloned by PCR from L. major total DNA as a complete 846-bp gene, which was then sequenced and found to conform to the data base sequence. Alignment of LtAQP1 and LmAQP1 with rat and human AQP9 protein sequences showed 40% overall sequence similarity with the mammalian homologues and 77% overall sequence similarity among themselves (Fig. 1) . Both sequences have six transmembrane segments and the four signature motifs (P1-P4) of known aquaglyceroporins. LmAQP1 was chosen for further analysis.
Expression of LmAQP1 Confers Metalloid Sensitivity in Leishmania-LmAQP1 was cloned in the Leishmania expression vector pSP72␣neo␣, and the resulting plasmid strain L. tarentolae. The L. tarentolae AQPneo strain exhibited a 1.5-fold increase in sensitivity to As(III) and a 2.0-fold increase in sensitivity to Sb(III). On the other hand, the L. infantum AQPneo strain became 250-and 2500-fold more sensitive to As(III) and Sb(III), respectively. The EC 50 of the L. major AQPneo strain was 15-fold lower for As(III) and 100-fold lower for Sb(III). Production of LmAQP1 in transfected L. tarentolae and L. infantum was detected by immunoblotting with antiserum raised against a peptide corresponding to residues 139 -152 of LmAQP1 (Fig. 2, B and C, insets) . Because expression of LmAQP1 increases transport across the plasma membrane, it is reasonable to assume that this protein is localized predominantly in that membrane.
By stepwise selection in vitro, we have isolated promastigotes of several strains that are resistant to Sb(III) and As(III) (29, 30) . Promastigotes selected against one metalloid were cross-resistant to the other (Table I) . Strikingly, when transfected with pSP-AQPneo, each resistant mutant became resensitized to both metalloids. The EC 50 of each transfected resistant mutant was even lower than its respective wild type levels (Table I) and was closer to values found in wild type cells transfected with LmAQP1.
LmAQP1 Facilitates Uptake of Sb(III) and As(III) in Leishmania Promastigotes-The ability of Leishmania AQP1 to transport Sb(III) and As(III) was investigated. LmAQP1 transfected strains L. tarentolae AQPneo, L. infantum AQPneo, and L. major AQPneo showed rapid uptake of Sb(III) (Fig. 2) and As(III) (Fig. 3 ) compared with transfectants with vector alone. Even though these channels do not catalyze net accumulation, binding to intracellular sites, metabolic alteration, or sequestration in organelles will result in an apparent accumulation of the metalloids; so, for all practical purposes, the assay measures accumulation. Each Leishmania species expressing LmAQP1 had much higher rates of uptake and exhibited an apparent steady state level of As(III) and Sb(III) that was 20 -50-fold more than the untransfected control. Although the L. tarentolae (wild type) strain also accumulated higher amounts of As(III) or Sb(III), it was less sensitive to the metalloids than other species. This could be because of an ability to sequester the metals more efficiently than others.
As described previously, most Leishmania species selected for resistance to As(III) or Sb(III) in vitro showed a reduced accumulation of the metalloids compared with the parental strains (29, 30) . When resistant mutants were transfected with pSP-AQPneo, they exhibited substantially higher rates of uptake and 50 -100-fold higher levels of intracellular Sb(III) (Fig.  4A) or As(III) (Fig. 4B) . We propose that the increase in the rate of uptake is responsible for resensitization of the resistant mutants to metalloids. This indicates that the uptake of Sb(III) may have become rate-limiting for drug action in these mutants.
LmAQP1 Sensitizes Antimony-resistant Field Isolates of L. donovani-A field isolate of L. donovani (FDA9518) from a patient who failed to respond to pentavalent antimonials therapy in India (31) and the corresponding sensitive strain (FDA9551) with similar karyotypes, as determined by pulse field gel electrophoresis, were transfected with LmAQP1. Both strains were 3-fold more sensitive to Pentostam (Fig. 5 and Table II) as amastigotes inside macrophages, compared with the strains transfected with vector alone. The resistant strain transfected with LmAQP1 was also much more sensitive to As(III) (40-fold) or Sb(III) (200-fold) (Table II) in vitro as promastigotes. These results suggest that uptake may be ratelimiting for Pentostam action in clinical isolates as well as resistant laboratory strains.
Disruption of an LmAQP1 Allele Confers Resistance-Because Leishmania is a diploid organism, it is necessary to disrupt the gene on both chromosomes to construct a homozygous knock-out organism. Presently we have constructed a heterozygous knock-out of L. major by disruption of one of the two alleles (Fig. 6A ). This single knock-out is 10-fold more resistant to Sb(III) than the homozygous wild type parent (Fig.  6B) . This supports our hypothesis that the amount of AQP1 in the plasma membrane is the rate-limiting step in uptake of the activated form of the antimonial drugs. It also strengthens the argument that point mutations in the AQP1 gene could give rise to clinical resistance. This is an important observation because it was not clear whether a single mutation would result in a sufficient reduction in uptake to produce resistance. Future studies will focus on the appearance of mutations in the AQP1 gene and the levels of AQP1 in the plasma membrane of field isolates of drug-resistant parasites. DISCUSSION We have identified a homologue of mammalian aquaglyceroporin, AQP9, in two strains of Leishmania. Leishmania AQP1 is clearly responsible for As(III) and Sb(III) uptake in Leishmania promastigotes and is likely the major route of uptake of trivalent metalloids. As such, AQP1 modulates drug sensitivity when expressed at increased levels in both promastigotes (Table I) and amastigotes (Fig. 5) . It increases the rate of uptake to such an extent that it can overcome any mechanism of resistance by flooding the cytosol with metalloid. The active component of Pentostam and Glucantime, the first line choices of drug treatment against all forms of leishmaniasis, is inorganic Sb(V). These drugs are formulations in which chelation of the Sb(V) with either gluconate (Pentostam) or the sorbitol derivative 1-deoxy-1-(methylamino)-D-glucitol (Glucantime) increase solubility. Sb(V) is taken up by both promastigotes and amastigotes (29) , although transporters for pentavalent antimony have not been identified. Axenic amastigotes of L. infantum, L. panamensis (29) , L. amazonensis (32) , and L. donovani (7) accumulate more Sb(V) than Sb(III). Despite this fact, an m-chlorocresol-free Sb(V) formulation has no leishmanicidal activity against either promastigotes or axenic amastigotes at pharmacological concentrations (6, 33, 34) . Additive-free Pentostam preparations, however, were as effective as the crude preparation against amastigotes grown inside of macrophages (6, 35, 36) , suggesting that macrophages are involved in Pentostam activity. We have recently observed that Sb(III)-resistant amastigotes of L. panamensis and L. infantum are crossresistant to Sb(V) when grown inside of macrophages, whereas Sb(III) is highly leishmanicidal against both forms of the parasite. 2 Previous studies found no correlation between clinical response and in vitro resistance to Sb(V) with the promastigote stage of the parasite (31); however, a correlation was observed with intracellular parasites (31) . Interestingly, we also observed a correlation between resistance to Sb(III) and to As(III) in both promastigotes and intracellular amastigotes (Table II) . Thus, it is reasonable to predict that a reduction of Sb(V) to Sb(III) is necessary for drug activation and that much of the reduction occurs in host macrophages. If so, then expression of amastigote AQP1 may be an important determinant in drug sensitivity. In addition, amastigotes generally are more sensitive to Sb(III) than promastigotes (29) , suggesting that AQP1 could be differentially regulated in the two developmental stages of the parasite. We have observed that the amastigotes expressing LmAQP1 inside of macrophages are less sensitive to Sb(V) than the promastigotes to Sb(III) ( bility is that the effective concentration of Sb(III) is low inside macrophages. This could also suggest that the rate of reduction is limiting in the macrophage or that some Sb(V) is directly transported into amastigotes before reduction by macrophages and thereby reduces the available concentration of Sb(III) in the macrophages. It is important, however, to note that LmAQP1 rendered the resistant strain as sensitive as the wild type. The magnitude of this effect is more than sufficient to reverse the drug resistance in the field.
Drug resistance is a major impediment to successful treatment of leishmaniasis (3, 4) . Down-regulation or loss of uptake systems has been shown to lead to drug resistance (11, 12) . Our results show that the loss of one AQP1 allele results in a 10-fold increase in drug resistance. It will be important to determine whether clinical drug resistance correlates with loss of AQP1 activity. Notably, the expression of AQP1 reverses metalloid resistance in several Leishmania strains selected for resistance in vitro or in field isolates. The mechanisms of resistance in some of these strains have been determined, and there is considerable diversity in the causes of resistance (37) . 2 This suggests that increasing expression of AQP1 can reverse resistance in diverse backgrounds of resistance. 
